Answers are grounded in this paper and cite their sources.
GH pulsatility is controlled by the coordinated release of stimulatory (Growth hormone-releasing hormone (GHRH) and the natural ligand of the GH secretagogue receptor (GH-S)) and inhibitory (somatostatin; SRIF) hypothalamic peptides ( Hartman et al., 1993 ; Bluet-Pajot et al., 1998 ). Inadequate GH secretion in children and adults is often due to an imbalance in the complex neuroendocrine network that regulates the release of GHRH, GH-S and SRIF. As a result of this imbalance, the ratio of GHRH + GH-S/SRIF tone decreases and a hyposomatotropic state ensues ( Martha et al., 1988 ; Ghigo et al., 1990a , and b; Satoet al., 1991 ; Volta et al., 1995 ). In children, low circulating levels of GH are responsible for short stature. In adults, age-related reductions in circulating GH cause a decrease in lean body mass, increase body fat and a decrease in bone mineral density ( Corpas et al., 1993a ). The undesirable effects of low circulating levels of GH can be diminished by the administration of human GH that is available through recombinant DNA technology. However, injection of this hormone does not mimic the normal pulsatile secretory profile ( Hartman et al., 1993 ). While this pharmacological dosing regimen may correct many of the effects of low circulating levels of GH, a more physiological pattern of administration would be expected to be safer and perhaps more effective ( Hindmarsh et al., 1992 ; Hartman et al., 1993 ). Concerns have been raised about the safety and efficacy of pharmacological doses of the drug in adults ( Chipman et al., 1997 ; Chan et al., 1998 ; Cuneo et al., 1998 ). Indeed, serious adverse effects of the drug have been noted, due in part to the manner in which it is administered. These include hyperglycemia, hypertension and carpal tunnel syndrome ( Vance, 1990; Ho & Hoffman, 1993). Therefore, a more physiological method of replacing systemic levels of GH is desired. Synthetic GHRH and/or GH-S can be administered to elevate systemic GH levels. Both secretagogues induce an immediate release of all of the forms of GH within the pituitary. This method of GH replacement is more physiological in that the pituitary response to the stimulus is modulated by the ambient negative feedback tone of the endocrine milieu ( Bellone et al., 1996 ; Bluet-Pajot et al., 1998 ). Thus, if a convenient mode of administration were available, GHRH and GH-S would be the therapy of choice to replace low levels of GH. Even more desirable would be a method that would allow for the resumption of normal GH pulses by resetting the hypothalamic GHRH + GH-S/SRIF balance. This would obviate the need for repeated administration. An interesting phenomenon has often been observed in basic and clinical studies that have examined the effect of both GH secretagogues on pituitary GH release. During the administration of either GHRH or GH-S, even in a continuous (nonpulsatile) fashion, endogenous pulses of pituitary GH are frequently observed. This has been demonstrated in children, adults and animal models with GH insufficiency ( Wehrenberg, 1986; Sassolas et al., 1986 ; Hulse et al., 1986 ; Rochiccioli et al., 1986 ; Brain et al., 1988 ; Hao et al., 1988 ; Martha et al., 1988 ; Ross et al., 1989 , 1990; DeBell et al., 1991 ; Low, 1991; Corpas et al., 1993b ; Huhn et al., 1993 ; Jaffe et al., 1993a ; Chapman et al., 1996 ; Thorner et al., 1997 ). These observations suggest that long-term stimulation of the pituitary with exogenous GH secretagogues allows it to become more responsive to endogenous GHRH and/or the endogenous ligand of the GH-S receptor. Thus, it may be possible to re-initiate normal pulses of GH that have been diminished or extinguished due to an imbalance between the releases of endogenous GH secretagogues and SRIF. The re-emergence of pituitary GH pulses after continuous infusion or oral secretagogue administration may be due to a variety of factors. These may include the direct or indirect reduction of SRIF tone, an increased release of endogenous GHRH or GHRP, increased pituitary sensitivity to endogenous GHRH pulses, increase in the readily releasable GH pool or some combination of the above. The anterior pituitary itself has the inherent capacity to release GH in a pulsatile fashion, albeit at very low amplitude ( Stewart et al., 1985 ). These pulses of pituitary GH may be the result of the inherent pacemaker activity of this tissue ( Guerineau et al., 1998 ). Endogenous pulses of hypothalamic GHRH, GH-S and SRIF may serve to organize and amplify this pacemaker activity into large pulsatile releases of GH. It has been reported that long-term pacemaker activity can be induced in cultured pituitary cells after only a short-term exposure to GHRH ( Kwiecien et al., 1997 ). Pacemaker activity is known to increase pituitary responsivity to GHRH and reduce the inhibitory effects of SRIF ( Lussier et al., 1991a , b, c). These observations, combined with the clinical data referenced above, suggest that it may be possible to re-entrain the hypothalamo-pituitary axis, through the administration of GHRH and/or GH-S. This would increase pituitary sensitivity to endogenous GHRH and GH-S and allow for a more physiological method to elevate systemic levels of GH. This review will describe the features of the neuroendocrine control over GH synthesis and release with special attention to methods that may elicit the reappearance of GH pulses. An understanding of this phenomenon may provide insight into the design of therapeutic molecules that could induce re-entrainment of GH pulses for prolonged periods of time and result in a much more physiological approach to GH replacement therapy. The pituitary synthesizes and secretes GH under the control of the hypothalamus. The release of GH is pulsatile and very tightly regulated ( Thorner et al., 1997 ). Specifically, two different classes of peptidergic neurones (stimulatory and inhibitory) are involved in the control of GH secretion. GHRH is synthesized primarily in the arcuate nucleus ( Bertherat et al., 1992 ) and stimulates GH synthesis and release upon binding to its receptor upon somatotrophs ( Barinaga et al., 1983 ). An as yet uncharacterized endogenous ligand (GH-S) of the recently cloned GH releasing peptide receptor is also thought to be synthesized in the arcuate nucleus and stimulates pituitary GH release ( Bluet-Pajot et al., 1998 ). SRIF is synthesized in the periventricular region of the hypothalamus and inhibits GH release from the pituitary. Information from the internal and external milieu is collected by the central nervous system and integrated at the level of the hypothalamus. That information is transmitted to the hypothalamic peptidergic neurones via synaptic transmission. All of this information is distilled into increases or decreases in GHRH, SRIF and presumably GH-S neuronal activity. A variety of different neurotransmitters are involved in the activation and/or inhibition of the GHRH, SRIF and GH-S neuronal networks. As a result, specific neurochemicals have been used to study the neuronal pathway leading to stimulation or inhibition of GH release. Many of these chemicals are used to determine the function of a patient's hypothalamo-pituitary axis. From these studies, an understanding of the hypothalamic regulation of GH release has emerged. Adrenergic agonists have a stimulatory effect upon GH secretion. Specifically, functional activation of alpha-2 adrenergic receptors by clonidine increases GHRH release from the hypothalamus and results in an increase in GH synthesis and release ( Magnan et al., 1994 ; De Gennaro Colonna et al., 1996 ). The stimulatory effect of clonidine may also be due to a concomitant reduction in hypothalamic SRIF secretion ( Devesa et al., 1991 ). Fourteen days of clonidine administration induces a pattern of GH secretion in old dogs that is indistinguishable from young ones and normal GH pulses are observed in those animals ( Cella et al., 1989 ). Chronic administration of clonidine to short stature children accelerates growth ( Loche et al., 1989 ). A second neurochemical method to increase GHRH tone is by the administration of an indirect cholinergic agonist (cholinesterase inhibitor), such as pyridostigmine (PD). This chemical increases the effectiveness of endogenous acetylcholine to reduce SRIF neuronal activity ( Penalva et al., 1990 ; Wehrenberg et al., 1992 ). Cholinesterase inhibitors also increase GHRH release from the hypothalamus of sheep ( Magnan et al., 1993 ). PD administration increases GH secretory burst activity in men of varying ages ( Friend et al., 1997 ). These observations are consistent with the hypothesis that stimuli capable of increasing the GHRH + GH-S/SRIF ratio are able to induce pituitary GH pulsatility. Hypothalamic GHRH, SRIF and potentially GH-S neurones are regulated by cholinergic and adrenergic input. Using pharmacological agents, it is possible to induce increase in the GHRH/SRIF ratio in pituitary portal blood and stimulate pituitary pulses of GH. In addition to adrenergic and cholinergic neurochemicals, the administration of certain amino acids induces GH release. Arginine is a well-known secretagogue of GH in man. It is thought to act through the inhibition of somatostatin neurones ( Alba-Roth et al., 1988 ; Ghigo et al., 1990a , b). Other amino acids, such as methionine, have also been shown to stimulate GH release ( Bellone et al., 1997 ). When arginine is coadministered with GHRH, a higher level of GH release is observed compared with the administration of either one alone ( Alba-Roth et al., 1988 ; Ghigo et al., 1990a , b). A normal response to arginine with a blunted GHRH response in short stature children suggests that this syndrome is due at least in part to excess somatostatin tone ( Sato et al., 1991 ). Infusion of arginine induces a reduction in somatostatin tone with a concomitant increase in relative GHRH stimulation and an increase in GH secretory dynamics ( Sato et al., 1990 ). Arginine and other amino acids increase calcium entry into anterior pituitary cells which would amplify pituitary responses to GHRH ( Villalobos et al., 1997 ). Thus, in addition to an effect upon GHRH and SRIF neurones, arginine may also have a direct pituitary effect. Results with all of these neurochemical manipulations demonstrate that GH secretory dynamics can be dramatically improved by manipulations that increase the GHRH/SRIF ratio. In short stature children, GHRH provocation of GH release is more effective when the treatment is combined with pyridostigmine or arginine ( Ross et al., 1989 ; Ghigo et al., 1990a , b). GHRH is synthesized in specialized neurones within the arcuate nucleus of the hypothalamus and released at the level of the median eminence into the pituitary portal vasculature. GHRH travels to the anterior pituitary gland where it binds with high affinity to a member of the G protein coupled receptor gene family ( Gaylinn et al., 1993 ). Following activation of the GHRH receptor, adenylate cyclase is stimulated which results in an increase in intracellular levels of c-AMP and GH gene expression is increased ( Barinaga et al., 1983 ). In addition, receptor activation stimulates a voltage-dependent stimulus-secretion coupled event mediated by an influx in extracellular calcium into the cell ( Kato et al., 1992 ; Kato & Sakuma, 1997). GH is released in a pulsatile fashion following the activation of the GHRH receptor present upon the anterior pituitary gland ( Frohman et al., 1992 ). As described below, GHRH receptor activation not only stimulates an acute release of GH from these cells, but also synchronizes spontaneous coactivation of neighbouring cells. This phenomenon is thought to increase pituitary responsivity to subsequent GHRH volleys as well as organize and amplify autonomous GH secretion ( Guerineau et al., 1998 ). Pulses of GH are facilitated not only by a stimulatory effect of GHRH upon pituitary cells but by a cooperative interaction with somatostatin ( Thorner et al., 1990 ). Somatostatin is synthesized within neurones of the periventricular nucleus and transported through the pituitary portal circulation for delivery to the pituitary. SRIF is a direct inhibitor of pituitary GH release ( Frohman et al., 1992 ). The reciprocal relationship between the GHRH and SRIF is assumed to optimize GHRH-induced GH release ( Tzanela et al., 1996 ). Following the acute withdrawal of SRIF, the stimulatory effects of a GHRH pulse are amplified ( Plotsky & Vale, 1985; Ho et al., 1993 ; Cella et al., 1996 ). As mentioned above, arginine is thought to increase GH release from the pituitary by the inhibition of SRIF tone. This increase cannot occur solely by a reduction of SRIF, but by a concomitant increase in GHRH release as well ( Ho et al., 1993 ; Jaffe et al., 1996 ). Somatostatin acutely inhibits GH pulses, which may enhance the response to subsequent GHRH-stimulated GH pulses ( Tannenbaum, 1988; Tzanela et al., 1996 ). SRIF is also released intrahypothalamically to inhibit the activity of GHRH neurones and prevent GHRH release ( Bertherat et al., 1993 ; Tannenbaum et al., 1998 ). The originally identified GH secretagogues were hexapeptides ( Bowers et al., 1991 ). They are able to induce GH release regardless of the route of administration ( Camanni et al., 1998 ). More recently, nonpeptidyl secretagogues have been synthesized and studied in animals and humans ( Smith et al., 1993 , 1997; Arvat et al., 1997 ; Ghigo et al., 1998 ). These molecules have GH-releasing capacity and induce GH release by activating a receptor other than GHRH ( Cheng et al., 1989 ). Specific receptors for GHRPs and the nonpeptidyl secretagogues have been demonstrated on both the pituitary and in the hypothalamus ( Bowers et al., 1991 ; Howard et al., 1996 ; Muccioli et al., 1998 ). Using an expression cloning assay, the receptor for these synthetic secretagogues was identified ( Howard et al., 1996 ). The receptor is a member of G protein coupled receptor system (as is the GHRH receptor). GH-S have been shown to bind with high affinity to this receptor and affect intracellular potassium and calcium ion conductance in pituitary cells. The synthetic secretagogues appear to act as functional GHRH agonists and somatostatin antagonists ( Smith et al., 1997 ). Co-administration of GH-S with GHRH induces a synergistic effect upon GH release ( Arvat et al., 1997 ; Massoud et al., 1997 ), supporting the binding data that demonstrates that the two GH secretagogues act at distinct receptors. Withdrawal of SRIF enhances the GH response to GH-S, probably the result of endogenous release of GHRH that synergizes with GH-S ( Massoud et al., 1997 ). The complex interrelationship between GHRH, GH-S and SRIF ensures physiologically appropriate GH pulses. Changes in the GHRH + GH-S/SRIF ratio affect both the timing ( Thorner et al., 1990 ) and the amplitude ( Kraicer et al., 1988 ) of GH pulses from the pituitary. However, when the temporal aspects of the pulsatile control of the opposing hypothalamic signals lose synchronicity, a reduction in the GHRH + GH-S/SRIF ratio causes a diminution of GH pulses. Reductions in circulating GH levels in children with short stature, in aged adults and obese individuals has been ascribed to this reduced GHRH + GH-S/SRIF ratio ( Martha et al., 1988 ; Thorner et al., 1990 ). As a result of decreased stimulation, GHRH receptor level density declines, pituitary GH stores are diminished and the sensitivity to subsequent GHRH and GH-S challenges is reduced ( Thorner et al., 1990 ; Frohman et al., 1992 ; Friend et al., 1997 ). In the normal individual, GHRH responses are relatively constant during puberty, and decline slowly thereafter. This reduction in GHRH effectiveness is not due to decline in pituitary reserve of GH, but a decrease in the GHRH + GH-S/SRIF tone ( Tannenbaum, 1988; Penalva et al., 1990 ; Muller et al., 1993 ). SRIF withdrawal is an effective generator of pulsatile GH release by allowing for an increase in the functional activity of GHRH-secreting neurones in the hypothalamus ( Cella et al., 1996 ). Withdrawal of SRIF results in a higher endogenous GHRH + GH-S/SRIF ratio that would be expected to increase the GH pulse amplitude and increase GH synthesis within the pituitary, making more GH available for release. A similar effect can be observed by the administration of an antibody against somatostatin ( Tannenbaum, 1988). Neurochemically induced somatostatin inhibition or direct immunoneutralization of somatostatin raises not only trough levels of GH but also enhances the GHRH-induced GH pulsatile release ( Jacovidou & Patel, 1987). These results are consistent with the suggestion that the increasing the ratio of GHRH + GH-S/SRIF results in the appearance of accentuated GH pulses from the pituitary. These pulses are most likely due to the enhanced sensitivity of the pituitary to endogenous GHRH release. When GH-S are administered acutely to the elderly, their effectiveness is reduced, due most likely to a decreased endogenous GHRH + GH-S/SRIF ratio ( Ghigo et al., 1996 ; Camanni et al., 1998 ). Long-term oral administration of GH-S can, this and stimulate pulsatile GH secretion in a fashion similar to young adults ( Thorner et al., 1997 ). The results demonstrate that endogenous GHRH secretagogues and potentially and SRIF are released in a coordinated fashion to stimulate pulsatile GH secretion. In addition to an acute administered GHRH and GH-S either alone or in are able to the GHRH + GH-S/SRIF tone to allow for the re-emergence of endogenous GHRH induced GH pulses in regulation of GH at both the hypothalamic and pituitary levels. GHRH and SRIF neurones are by circulating levels of GH and GH regulates its synthesis and release by hypothalamic GHRH tone and GHRH receptor density ( Bertherat et al., 1993 ; et al., 1998 ) and increasing somatostatin ( De Gennaro et al., 1993 ). of GH to animals an increase in somatostatin receptors ( et al., 1996 ). The negative feedback of GH at the level of the hypothalamus to decrease GHRH activation through somatostatin This is by the of GH to induce negative feedback in that have the somatostatin receptor ( et al., 1997 ). GH may its secretion through the regulation of somatostatin receptors in the hypothalamus GHRH GH receptors have been demonstrated in the hypothalamus ( et al., 1993 ). Thus, GH may act upon the arcuate ( et al., 1998 ) and periventricular ( et al., 1992 ) to gene expression of GHRH and SRIF. GH receptors are upon neurones within the hypothalamus ( et al., 1992 ). both peptides can inhibit other in a reciprocal manner ( Bluet-Pajot et al., 1998 ). A direct reciprocal between SRIF and GHRH neurones in the hypothalamus ( et al., 1989 ; et al., 1989 ; et al., 1994 ). SRIF has not only a direct effect upon the release of GH from the pituitary gland but upon the release of hypothalamic GHRH as GHRH neurones SRIF receptors ( Bertherat et al., 1992 ; et al., 1992 ; Tannenbaum et al., 1998 ). of SRIF receptors inhibits release of GHRH from these with SRIF results in an increase in GHRH within the portal circulation ( Plotsky & Vale, In addition to an feedback of GH upon GHRH a and a direct control as well to control the timing and of GH pulses. affect the release of GH. During puberty, GH pulse amplitude is increased through an has a similar most likely through the of to to its effect ( et al., 1996 ). The effect of to be at the level of GHRH not SRIF pulsatile that GH synthesis and secretion. During puberty, the increase in GH secretion is by an increase in GH pulse amplitude than ( et al., ). This effect to be due to an increase in GHRH pulse amplitude and not a induced decrease in somatostatin An increase in body fat is known to decrease the secretion of GH in adults and children ( Thorner et al., 1997 ). children are not obese not to arginine short stature obese children a normal GH Thus, the neuroendocrine regulation of GH to be similar in normal and obese This suggests that decreases in the GHRH + GH-S/SRIF tone are responsible for levels of GH secretion in obese children ( Volta et al., 1995 ). these results suggest that the regulation of GH pulses are the result of regulated hypothalamic GHRH and perhaps GH-S releases that are upon a pattern of somatostatin release ( Jaffe et al., 1993a , b, The neuroendocrine system is responsive to a variety of and endocrine feedback In normal children, pulses of GH are to be of a of with large increases in amplitude of the pulses observed at the time of ( Hindmarsh et al., 1988 ). all of the GH pulses observed are due to the effects of GHRH and perhaps GH-S on the pituitary gland and not a withdrawal of SRIF ( et al., 1996 ). adults also pulsatile releases of GH as ( et al., 1990 ). in the pulsatile release of GH are observed and as mentioned above, are thought to be due primarily to a relative decrease in the GHRH + GH-S/SRIF tone ( et al., 1997 ). children with GH release are also assumed to have a reduced GHRH + GH-S/SRIF ratio. Chronic infusion of GHRH results in of pulses of pituitary GH ( et al., 1985 ; et al., 1985 ; Hulse et al., 1986 ; Sassolas et al., 1986 ; Brain et al., 1988 ; Low, 1993). In most the treatment increased not only the of GH pulses, but also the pulse and amplitude ( Sassolas et al., 1986 ). The of of GHRH to induce pulses of GH release has been reported in short stature children ( Rochiccioli et al., 1986 ; Smith et al., 1986 ; Ross et al., 1989 , old men ( Corpas et al., 1993 and normal ( Wehrenberg, infusion of GHRH to normal adults or GH children is not with pituitary ( Brain et al., 1988 ; Low, 1993). Endogenous pulses of GH have been observed in men and after of GH-S ( DeBell et al., 1991 ; Huhn et al., 1993 ; Jaffe et al., 1993a ) and the nonpeptidyl ( Chapman et al., 1996 ). GH-S infusion increased GH pulse amplitude as well as the responsivity of the pituitary to The pulse not in most the pulse amplitude was enhanced ( Jaffe et al., 1993a ). This the that the administration of exogenous GHRH and/or GH-S increase the GHRH + GH-S/SRIF ratio to allow for an increased pituitary sensitivity to endogenous GHRH It may be that treatment with GH secretagogues the pituitary response to endogenous GHRH pulses and allows the pituitary to GH pulses. This may be due to a increase in the GHRH pulse the SRIF tone, increasing the pituitary response to GHRH or increasing the readily releasable pool of GH combination of the The of anterior pituitary cells are to all These cells spontaneous and calcium ( et al., 1991 ; Kwiecien & are known to a spontaneous in intracellular calcium levels due to calcium entry into the cell through calcium ( et al., 1992 ; Kato et al., 1992 ). GHRH stimulates the synthesis and release of GH from pituitary cells. Following binding of the ligand to its receptor, GHRH receptor activation stimulates a increase in intracellular ( et al., 1992 ). of pituitary cells in to GHRH results in a large increase in GH release compared with secretion ( et al., 1989 ). of calcium prevent this GHRH-stimulated secretion ( Lussier et al., 1991a , b, al., 1992 ; Kato et al., 1992 ). This spontaneous activity has been the and even in the of GHRH stimulation ( Kwiecien & and in ( et al., 1991 ; Kwiecien et al., 1998 ). It is thought that this pacemaker activity is to the cell to the exposure to The pacemaker activity that even in the of GHRH is not to induce secretion of GH. However, it increases dramatically when GHRH its receptor. An increase in + + and of is observed ( Lussier et al., 1991a ; et al., 1991 ) and this induces a release of the readily releasable pool of GH ( Kwiecien & A exposure of GHRH is by increased of + that for to after the GHRH ( Kwiecien et al., 1997 ). This allows for the release of large short of GH from the pituitary gland after stimulation of the receptor. Thus, a stimulus such as GHRH may be able to organize and amplify this inherent activity of the pituitary ( Stewart et al., 1985 ). The addition of somatostatin induces a reduction in the pacemaker activity of the cells which inhibits GH secretion and decreases the sensitivity of the cell to GHRH Somatostatin entry into the cells and calcium as well as responses to GHRH ( et al., ; Lussier et al., ; et al., 1991 ; et al., 1992 ). GHRH increases conductance within the responsive cell which results in the of the cell ( et al., 1990a ; Kato & Sakuma, 1997). This stimulates influx through calcium A similar effect of GH-S was observed with and ( & & Somatostatin the GHRH induced increase in by increasing and the This would the calcium leading to a decrease in influx and a in intracellular calcium ( Lussier et al., , c). From a it is that prolonged exposure of pituitary cells to GHRH could be to the inhibitory effects of SRIF These would include increases in GHRH receptor GH releasable ion cell and All of these would increase the pituitary response to endogenous GHRH pulses. features of to many other neuroendocrine cells and neurones ( et al., 1990 ). In most of the studies above, activation of cells by the addition of GHRH or an agonist results in a pattern of and in calcium cells that results in a pulse of GH into the systemic pituitary and pituitary tissue in also pulsatile GH release ( Stewart et al., 1985 ; & 1990; Kwiecien et al., 1998 ). This suggests that is a within to it has been shown that of cells within the an inherent pulsatile spontaneous pattern of into the cells ( Guerineau et al., 1998 ). pituitary cells with which results in coactivation and secretion. This of would allow for GHRH, GH-S and somatostatin to organize responses to GH pulses from the pituitary Indeed, in studies with GH it has been shown that administration of the agonist increased the amplitude of GH pulses, but not the of pulses ( Thorner et al., 1997 ), a of cells that are able to GH. These of provide a for a response to hypothalamic pacemaker activity can be induced by relatively short to GHRH ( Kwiecien et al., 1997 ). This of the for the of GH pulses following the of GHRH and/or GH-S administration. over the pulsatile release of GH from the pituitary gland is A in of the to the of physiological pulses results in an inhibition of GH secretion. of the reductions in the ratio results in an inhibition of GH pulse release. and clinical studies to demonstrate that in these the administration of GHRH or GH-S either alone or in can induce an acute release of GH. even if not allows for the re-emergence of pituitary GH pulses, presumably due to the increased sensitivity to endogenous GHRH release. The pulses of pituitary GH that occur during of GHRH or GH-S suggest that the increased GHRH + GH-S/SRIF ratio increases pituitary GHRH This increased GHRH sensitivity may after the exogenous secretagogue therapy is While is clinical that a re-entrainment of GH pulses following the of long-term GHRH suggest would be The combination of an increased expression of pituitary GHRH an increase in the GH releasable pool and increased pituitary cell responses to GHRH after GH secretagogue therapy may allow for re-entrainment of endogenous GH pulses after exogenous GHRH administration is GHRH has been shown to have effects upon within GHRH has the to enhance the response to subsequent stimuli by ion within the of this neighbouring cells to even if not The result is an of response to subsequent It may be that long-term stimulation of pituitary cells with GHRH will the GHRH/SRIF tone by exogenous therapy to increase GHRH responsivity and pituitary GH It is that this therapy will the inhibitory state induced by long-term SRIF and an responsive to the endogenous GHRH tone. Thus, this re-entrainment therapy may the system to one of GHRH than SRIF and allow for the normal pulsatile GH release to This would a therapeutic and a safety profile compared with of a of recombinant GH. this repeated stimulation of GHRH receptors is in a This may be with the of GHRH agonists or other methods to induce pituitary GH synthesis and such as ( et al., 1995 ). are to these molecules to this
No takes yet. Share an insight, caveat, or question.
Scott C. Chappel (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: